ADAR1 Capital Management LLC Grows Stock Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

ADAR1 Capital Management LLC lifted its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 196.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 169,505 shares of the company’s stock after buying an additional 112,339 shares during the quarter. ADAR1 Capital Management LLC owned approximately 0.51% of Lexeo Therapeutics worth $1,115,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Aristides Capital LLC acquired a new stake in shares of Lexeo Therapeutics during the fourth quarter worth about $193,000. Wells Fargo & Company MN increased its stake in shares of Lexeo Therapeutics by 49.9% during the fourth quarter. Wells Fargo & Company MN now owns 11,156 shares of the company’s stock worth $73,000 after purchasing an additional 3,714 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Lexeo Therapeutics by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 567,383 shares of the company’s stock worth $3,735,000 after acquiring an additional 14,136 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Lexeo Therapeutics by 48.3% during the fourth quarter. Wellington Management Group LLP now owns 76,981 shares of the company’s stock worth $507,000 after buying an additional 25,089 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Lexeo Therapeutics by 30.1% in the 4th quarter. JPMorgan Chase & Co. now owns 13,371 shares of the company’s stock valued at $88,000 after acquiring an additional 3,093 shares during the last quarter. Institutional investors own 60.67% of the company’s stock.

Analyst Upgrades and Downgrades

LXEO has been the subject of a number of recent analyst reports. Royal Bank of Canada cut their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, March 25th. HC Wainwright reaffirmed a “buy” rating and set a $23.00 target price on shares of Lexeo Therapeutics in a research note on Wednesday, March 26th. Leerink Partners decreased their price objective on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Monday, March 24th. Finally, Chardan Capital reissued a “buy” rating and issued a $25.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, March 25th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $22.80.

Lexeo Therapeutics Trading Down 11.4 %

Shares of LXEO stock opened at $2.34 on Monday. The firm has a market cap of $77.68 million, a P/E ratio of -0.74 and a beta of 1.52. The firm’s 50-day simple moving average is $3.82 and its 200-day simple moving average is $6.29. Lexeo Therapeutics, Inc. has a 1-year low of $2.27 and a 1-year high of $19.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09. As a group, equities analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.